AtriCure 10-Q: Q3 Revenue $154.5M, First Nine-Month Profit, $260M SentreHEART Suit Detailed
ATRC has more than doubled off its 52-week low of $25.36.
Summary
AtriCure's Q3 10-Q confirms $154.5M revenue (+15.0%) and $4.1M net income, with nine-month profit of $13.1M versus a year-ago loss, $187.0M of cash, and a SentreHEART lawsuit seeking up to $260.0M that carries no booked liability.
Key Events · Earnings and Guidance · ATRC
-
Q3 Revenue Up 15.0% to $154.5M
Worldwide revenue rose 15.0% to $154,450 thousand from $134,269 thousand, with U.S. revenue up 17.1% to $128,049 thousand on pain management (+34.6%) and open ablation (+20.8%).
-
Nine-Month Swing to $13.1M Profit
Nine-month net income was $13,127 thousand versus a $13,204 thousand loss in 2025; Q3 gross margin improved to 77.3% from 75.5%, while R&D rose 40.3% to $32,116 thousand including a $4,500 thousand acquired IPR&D milestone.
-
$260M SentreHEART Suit, No Liability Booked
Former SentreHEART securityholders seek damages of up to $260,000 thousand plus interest; no liability is recognized because any potential loss is not currently probable or reasonably estimable.
-
Cash $187.0M Against $61.0M Drawn
Cash and equivalents were $187,031 thousand with $61,000 thousand drawn on the $125,000 thousand ABL facility and $62,750 thousand unused capacity; a $23,287 thousand finance lease liability was recorded as the Mason, Ohio expansion was completed.
Analysis · ATRC · Industrial Applications And Services
The 10-Q backs up the prior day's headline Q3 release with the full picture: revenue of $154.5M (+15.0%) and net income of $4.1M, lifting the nine-month result to $13.1M of profit versus a $13.2M loss a year earlier. Gross margin improved to 77.3% from 75.5%, but R&D jumped 40.3% to $32.1M, including a $4.5M acquired IPR&D milestone payment, so operating leverage is thinner than the top line suggests. The balance sheet is comfortable — $187.0M of cash against $61.0M drawn on the ABL facility — but the filing also puts a hard number on the SentreHEART dispute: former securityholders seek up to $260.0M plus interest, and no liability is booked because management says a loss is not probable or reasonably estimable. That claim is the single largest swing factor in the equity story.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRC was trading at $64.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $25.36 to $65.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.